744 related articles for article (PubMed ID: 18303485)
1. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
[TBL] [Abstract][Full Text] [Related]
5. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
[TBL] [Abstract][Full Text] [Related]
6. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
9. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
10. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
11. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
12. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Montero AJ; Rouzier R; Lluch A; Theriault RL; Buzdar AU; Delaloge S; Bermejo B; Le M; Kau SW; Dunant A; Arriagada R; Spielmann M; Garcia-Conde J; Sahin AA; Singletary SE; Hortobagyi GN; Valero V
Cancer; 2005 Jul; 104(2):229-35. PubMed ID: 15937910
[TBL] [Abstract][Full Text] [Related]
13. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
[TBL] [Abstract][Full Text] [Related]
14. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
15. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
17. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
19. [The clinical course and treatment results of lung metastases from breast cancer].
Xu B; Zhou J; Zhou A
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):274-6. PubMed ID: 11038757
[TBL] [Abstract][Full Text] [Related]
20. [Primary breast lymphoma--a report of 27 cases with literature review].
Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
